{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/29318"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/29318","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"The role of FVIII/Anti-FVIII antibody Immune Complexes in Preventing FVIII-Specific Antibody Production in a Hemophilia A Mouse Model","abstract":"Abstract Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs. Binding rhFVIII/anti-FVIII immune complexes (rhFVIII-ICs) to FcγRIIB (CD32b) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM) tail of CD32b, resulting in the transduction of inhibitory signals to B cells, thereby inhibiting antibody production. Aim: To evaluate the effect of rhFVIII-ICs administration on the suppression of antibody production by B cells in a mouse model. Methods: A high-affinity anti-FVIII IgG pool was obtained by immunizing of FVIII KO mice with rhFVIII (Kovaltry). After immunization, blood was collected from immunized mice, and plasma was obtained. rhFVIII-ICs were prepared by incubating the mice plasma or anti-FVIII monoclonal antibody pool with Kovaltry at 1:1 and 1:10 ratios. FVIII KO mice were injected retro-orbitally with rhFVIII-ICs, PBS, or Kovaltry diluted in naïve plasma once weekly for four weeks (tolerization phase). Next, the mice were administered with FVIII retro-orbitally at a dose of 25 IU/kg once weekly for four weeks. Finally, blood samples were collected from all mice, and ELISA determined the concentration of anti-FVIII IgG. Results: Mice that received the combination of FVIII and naive plasma developed anti-FVIII IgG (mean increase 6.1 μg/mL, p-value = 0.0001). In contrast, 69% of mice that received 1:1 rhFVIII-ICs did not develop antibodies (mean increase 1.3 μg/mL, p-value = 0.0723), while 50% of the mice that received 1:10 rhFVIII-ICs did not develop antibodies (mean increase 2.3 μg/mL, p-value = 0.1030). Conclusion: In this study, we demonstrated that a 1:1 balanced ratio of rhFVIII-ICs injection suppresses antibody production. Thus, antibody feedback may play a role in the immune response to FVIII by suppressing FVIII-specific B cells. Future work will investigate the mechanism of this suppression, particularly the potential involvement of CD32b.","abstract_html":"Abstract Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs. Binding rhFVIII/anti-FVIII immune complexes (rhFVIII-ICs) to FcγRIIB (CD32b) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM) tail of CD32b, resulting in the transduction of inhibitory signals to B cells, thereby inhibiting antibody production. Aim: To evaluate the effect of rhFVIII-ICs administration on the suppression of antibody production by B cells in a mouse model. Methods: A high-affinity anti-FVIII IgG pool was obtained by immunizing of FVIII KO mice with rhFVIII (Kovaltry). After immunization, blood was collected from immunized mice, and plasma was obtained. rhFVIII-ICs were prepared by incubating the mice plasma or anti-FVIII monoclonal antibody pool with Kovaltry at 1:1 and 1:10 ratios. FVIII KO mice were injected retro-orbitally with rhFVIII-ICs, PBS, or Kovaltry diluted in naïve plasma once weekly for four weeks (tolerization phase). Next, the mice were administered with FVIII retro-orbitally at a dose of 25 IU/kg once weekly for four weeks. Finally, blood samples were collected from all mice, and ELISA determined the concentration of anti-FVIII IgG. Results: Mice that received the combination of FVIII and naive plasma developed anti-FVIII IgG (mean increase 6.1 μg/mL, p-value = 0.0001). In contrast, 69% of mice that received 1:1 rhFVIII-ICs did not develop antibodies (mean increase 1.3 μg/mL, p-value = 0.0723), while 50% of the mice that received 1:10 rhFVIII-ICs did not develop antibodies (mean increase 2.3 μg/mL, p-value = 0.1030). Conclusion: In this study, we demonstrated that a 1:1 balanced ratio of rhFVIII-ICs injection suppresses antibody production. Thus, antibody feedback may play a role in the immune response to FVIII by suppressing FVIII-specific B cells. Future work will investigate the mechanism of this suppression, particularly the potential involvement of CD32b.","abstract_has_math":false,"creators":["Dadashi Zadeh, Ghazaleh"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Blood and Cardiovascular)","school":null,"contributors":[],"advisors":["Matino, Davide"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-18T19:38:47Z","subjects":["Hemophilia A","Mouse Model","Inhibitor","Anti-FVIII antibody"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/21944"],"render_values":[{"text":"https://doi.org/10.71548/21944","href":"https://doi.org/10.71548/21944","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/29318","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/29318","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F29318","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Matino, Davide"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Blood and Cardiovascular)"]},{"key":"dc:creator","label":"Author","values":["Dadashi Zadeh, Ghazaleh"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-01-04T16:27:29Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-01-04T16:27:29Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Hemophilia A","Mouse Model","Inhibitor","Anti-FVIII antibody"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/29318","https://doi.org/10.71548/21944"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Abstract Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs. Binding rhFVIII/anti-FVIII immune complexes (rhFVIII-ICs) to FcγRIIB (CD32b) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM) tail of CD32b, resulting in the transduction of inhibitory signals to B cells, thereby inhibiting antibody production. Aim: To evaluate the effect of rhFVIII-ICs administration on the suppression of antibody production by B cells in a mouse model. Methods: A high-affinity anti-FVIII IgG pool was obtained by immunizing of FVIII KO mice with rhFVIII (Kovaltry). After immunization, blood was collected from immunized mice, and plasma was obtained. rhFVIII-ICs were prepared by incubating the mice plasma or anti-FVIII monoclonal antibody pool with Kovaltry at 1:1 and 1:10 ratios. FVIII KO mice were injected retro-orbitally with rhFVIII-ICs, PBS, or Kovaltry diluted in naïve plasma once weekly for four weeks (tolerization phase). Next, the mice were administered with FVIII retro-orbitally at a dose of 25 IU/kg once weekly for four weeks. Finally, blood samples were collected from all mice, and ELISA determined the concentration of anti-FVIII IgG. Results: Mice that received the combination of FVIII and naive plasma developed anti-FVIII IgG (mean increase 6.1 μg/mL, p-value = 0.0001). In contrast, 69% of mice that received 1:1 rhFVIII-ICs did not develop antibodies (mean increase 1.3 μg/mL, p-value = 0.0723), while 50% of the mice that received 1:10 rhFVIII-ICs did not develop antibodies (mean increase 2.3 μg/mL, p-value = 0.1030). Conclusion: In this study, we demonstrated that a 1:1 balanced ratio of rhFVIII-ICs injection suppresses antibody production. Thus, antibody feedback may play a role in the immune response to FVIII by suppressing FVIII-specific B cells. Future work will investigate the mechanism of this suppression, particularly the potential involvement of CD32b."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["The role of FVIII/Anti-FVIII antibody Immune Complexes in Preventing FVIII-Specific Antibody Production in a Hemophilia A Mouse Model"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Matino, Davide"],"dc:contributor.department":["Medical Sciences (Blood and Cardiovascular)"],"dc:creator":["Dadashi Zadeh, Ghazaleh"],"dc:date.accessioned":["2024-01-04T16:27:29Z"],"dc:date.available":["2024-01-04T16:27:29Z"],"dc:date.issued":["2024"],"dc:description.abstract":["Abstract Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs. Binding rhFVIII/anti-FVIII immune complexes (rhFVIII-ICs) to FcγRIIB (CD32b) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM) tail of CD32b, resulting in the transduction of inhibitory signals to B cells, thereby inhibiting antibody production. Aim: To evaluate the effect of rhFVIII-ICs administration on the suppression of antibody production by B cells in a mouse model. Methods: A high-affinity anti-FVIII IgG pool was obtained by immunizing of FVIII KO mice with rhFVIII (Kovaltry). After immunization, blood was collected from immunized mice, and plasma was obtained. rhFVIII-ICs were prepared by incubating the mice plasma or anti-FVIII monoclonal antibody pool with Kovaltry at 1:1 and 1:10 ratios. FVIII KO mice were injected retro-orbitally with rhFVIII-ICs, PBS, or Kovaltry diluted in naïve plasma once weekly for four weeks (tolerization phase). Next, the mice were administered with FVIII retro-orbitally at a dose of 25 IU/kg once weekly for four weeks. Finally, blood samples were collected from all mice, and ELISA determined the concentration of anti-FVIII IgG. Results: Mice that received the combination of FVIII and naive plasma developed anti-FVIII IgG (mean increase 6.1 μg/mL, p-value = 0.0001). In contrast, 69% of mice that received 1:1 rhFVIII-ICs did not develop antibodies (mean increase 1.3 μg/mL, p-value = 0.0723), while 50% of the mice that received 1:10 rhFVIII-ICs did not develop antibodies (mean increase 2.3 μg/mL, p-value = 0.1030). Conclusion: In this study, we demonstrated that a 1:1 balanced ratio of rhFVIII-ICs injection suppresses antibody production. Thus, antibody feedback may play a role in the immune response to FVIII by suppressing FVIII-specific B cells. Future work will investigate the mechanism of this suppression, particularly the potential involvement of CD32b."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/29318","https://doi.org/10.71548/21944"],"dc:language.iso":["en"],"dc:subject":["Hemophilia A","Mouse Model","Inhibitor","Anti-FVIII antibody"],"dc:title":["The role of FVIII/Anti-FVIII antibody Immune Complexes in Preventing FVIII-Specific Antibody Production in a Hemophilia A Mouse Model"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:38:47Z"}